The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
Abstract
Purpose: To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer. Patients and Methods: This multicenter phase III trial randomly assigned 916 patients with hormone receptor–positive or unknown tumors letrozole 2.5 mg (n = 458) or tamoxifen 20 mg (n = 458) daily until disease progression. Optional cross-over was permitted at the treating physician’s discretion. This report updates efficacy at a median follow-up of 32 months. Results: The superiority of letrozole to tamoxifen was confirmed for time to progression (median, 9.4 v 6.0 months, respectively; P < .0001), time to treatment failure (median, 9 v 5.7 months, respectively; P < .0001), overall objective response rate (32% v 21%, respectively; P = .0002), and overall clinical benefit. Median OS was slightly prolonged for the randomized letrozole arm (34 v 30 months, respectively). Although this difference in OS is not significant, survival was improved in the randomized letrozole arm over the first 2 years of the study. Approximately one half of the patients in each arm crossed over. Total duration of endocrine therapy (“time to chemotherapy”) was significantly longer (P = .005) for patients initially on letrozole (median, 16 months) than for patients initially on tamoxifen (median, 9 months). Time to worsening of Karnofsky performance score was significantly delayed with letrozole compared with tamoxifen (P = .001). Conclusion: This study documents the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Self-citationNabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 259
Self-citationNabholtz, J. M., Bonneterre, J., Buzdar, A., Robertson, J. F. R., & Thürlimann, B. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00326-5 · Cited by 176
Cited by
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
“500 mg, every 4 weeks) [77–88].”
Oktay, K., Buyuk, E., Libertella, N., Akar, M., & Rosenwaks, Z. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.037 · Cited by 528
Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Fertility preservation in female patients
Sonmezer, M. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh021 · Cited by 496
Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Voi, M., Gnant, M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1279 · Cited by 494
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Is dehydroepiandrosterone a hormone?
Labrie, F., Luu-The, V, Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., & Labrie, C. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06264 · Cited by 451
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Oktay, K., Hourvitz, A., Sahin, G., Oktem, O., Safro, B., Cil, A., & Bang, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0962 · Cited by 421
Howell, A., Robertson, J. F. R., Abram, P., Lichinitser, M. R., Elledge, R., Bajetta, E., Watanabe, T., Morris, C., Webster, A., Dimery, I., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.112 · Cited by 421
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
van de Velde, C. J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.-M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62312-4 · Cited by 372
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1523 · Cited by 368
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Wildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., Hurria, A., Extermann, M., Girre, V., Brain, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70378-9 · Cited by 338
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Semiglazov, V. F., Semiglazov, V. V., Dashyan, G. A., Ziltsova, E. K., Ivanov, V. G., Bozhok, A. A., Melnikova, O. A., Paltuev, R. M., Kletzel, A., & Berstein, L. M. (2007) · Cancer · doi:10.1002/cncr.22789 · Cited by 333
Aromatase inhibitors for breast cancer: lessons from the laboratory
Johnston, S. R. D., & Dowsett, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1211 · Cited by 326
Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319
Lønning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Øfjord, E. S., Paolini, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.097 · Cited by 295
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Fertility Preservation in Young Women Undergoing Breast Cancer Therapy
Sonmezer, M., & Oktay, K. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-422 · Cited by 261
Clines, G. A., & Guise, T. A. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00543 · Cited by 253
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub3 · Cited by 252
Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5831 · Cited by 238
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S.-A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00137 · Cited by 200
Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., et al. (2019) · Cancers · doi:10.3390/cancers11111661 · Cited by 70
“Selective estrogen receptor modulators (such as tamoxifen) [4], selective estrogen receptor down-regulators (SERDs, like fulvestrant [F]) [5,6] aromatase inhibitors (AIs; such asletrozole [7], anastrazole [8] or exemestane [9]) are the mainstay of anticancer endocrine therapy (ET) [10].”
BackgroundTherapeutic options for metastatic breast cancer
Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902834961 · Cited by 59
Neven, P., Markopoulos, C., Tanner, M., Marty, M., Kreienberg, R., Atkins, L., Franquet, A., Gnant, M., Neciosup, S., Tesarova, P., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.009 · Cited by 53
(2011) · Cited by 12
Metadata
- Authors
- Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P. P., Salminen, E., Snyder, R., Chaudri-Ross, H., Lang, R., Wyld, P., & Bhatnagar, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-06-01
- Volume
- 21
- Issue
- 11
- Pages
- 2101-2109
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133764838
- Cited by
- 746
- References
- 13
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.